Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by UroGen Pharma Ltd.

< Previous 1 2 3 4 Next >
The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Announces $120 Million Private Placement of Ordinary Shares
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Host UGN-102 Data Event on July 27, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Present at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Present at H.C. Wainwright BioConnect Conference
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Present at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Present at Evercore ISI 5th Annual Virtual HealthCONx Conference
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial Carcinoma
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Announces the Appointment of Dan Wildman to the UroGen Pharma Board of Directors
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.